CPhI Worldwide-organized by UBM (part of Informa PLC)- released part two of its annual report, evaluating the effects of regulatory diligence, trade agreements, and IP rights over the next five years. Two annual report experts believe that IPRs and trade agreements and regulator divergence could potentially have profound global impacts.
The full findings of the CPhI Annual Report include 12 in-depth expert contributions as well as the CPhI Manufacturing and Bio leagues tables, which will evaluate the relative reputations of each major pharma country.
To view the report, click here.
